AB120892
Anacardic acid, Histone acetyltransferase (HAT) inhibitor
Be the first to review this product! Submit a review
|
(2 Publications)
MW 348.52 g/mol, Purity >98%. Inhibits HAT activity of p300 and p300/CREB-binding protein-associated factor (pCAF) (IC50 = 8.5 and 5 μM, respectively). Suppresses NF-κB activation, inhibits IκBα phosphorylation and prohibits p65 nuclear translocation.
1 Images
- Chemical Structure
Lab
Chemical Structure - Anacardic acid, Histone acetyltransferase (HAT) inhibitor (AB120892)
2D chemical structure image of ab120892, Anacardic acid, Histone acetyltransferase (HAT) inhibitor
Properties and storage information
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
It is important to note that this product is reported to be light sensitive|Store in the dark|Store under desiccating conditions
Publications (2)
Recent publications for all applications. Explore the full list and refine your search
Journal of cell science 135: PubMed35510498
2022
Fluid shear stress regulates the survival of circulating tumor cells via nuclear expansion.
Applications
Unspecified application
Species
Unspecified reactive species
Zichen Xu,Keming Li,Ying Xin,Kai Tang,Mo Yang,Guixue Wang,Youhua Tan
Journal of cell science : PubMed33526713
2021
Nuclear localization of p65 reverses therapy induced senescence.
Applications
Unspecified application
Species
Unspecified reactive species
Sameer Salunkhe,Saket V Mishra,Jyothi Nair,Sanket Shah,Nilesh Gardi,Rahul Thorat,Debashmita Sarkar,Jacinth Rajendra,Ekjot Kaur,Shilpee Dutt
Complementary Products
Product promise
We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com